Head to Head Review: TNF Pharmaceuticals (NASDAQ:TNFA) vs. Zevra Therapeutics (NASDAQ:ZVRA)

TNF Pharmaceuticals (NASDAQ:TNFA) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Valuation & Earnings

This table compares TNF Pharmaceuticals and Zevra Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TNF Pharmaceuticals	N/A	N/A	-$23.36 million	($231.00)	-0.02
Zevra Therapeutics	$106.47 million	6.18	$83.23 million	$1.99	5.59

Zevra Therapeutics has higher revenue and earnings than TNF Pharmaceuticals. TNF Pharmaceuticals is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares TNF Pharmaceuticals and Zevra Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TNF Pharmaceuticals	N/A	-69.21%	-33.98%
Zevra Therapeutics	101.58%	51.49%	28.86%

Risk & Volatility

TNF Pharmaceuticals has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500.

Institutional & Insider Ownership

9.6% of TNF Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 0.5% of TNF Pharmaceuticals shares are owned by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for TNF Pharmaceuticals and Zevra Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TNF Pharmaceuticals	1	0	0	0	1.00
Zevra Therapeutics	0	1	8	0	2.89

Zevra Therapeutics has a consensus price target of $23.33, indicating a potential upside of 109.64%. Given Zevra Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Zevra Therapeutics is more favorable than TNF Pharmaceuticals.

Summary

Zevra Therapeutics beats TNF Pharmaceuticals on 12 of the 13 factors compared between the two stocks.

About TNF Pharmaceuticals

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

About Zevra Therapeutics

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.